Rotavirus vaccine

The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; the vaccine should be used with caution in those with immunosuppressed close contacts. Carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby€™s nappies. Rotavirus vaccine (live, oral) is licensed for immunisation of infants over 6 weeks of age for protection against gastro-enteritis caused by rotavirus infection.

Brands
ROTARIX
Adult Dose
Neonatal
Dose: 1
Single Dose: 1 (1)
Frequency: As recommended.
Route: PO
Instructions: Two doses are given, the first at 6 weeks of age onwards and the subsequent dose at least 4 weeks later; the course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks.
Paedriatic
Characteristics
Rotavirus vaccine also known as Vacunas de rotavirus. . It is of Natural origin. .
Contraindications
Rotavirus vaccine is contraindicated in conditions like Immune system weakness,Intussusception.
Effects
The symptomatic adverse reactions produced by Rotavirus vaccine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Irritability, Vomiting, Anorexia, Diarrhea, Fever, Abdominal pain, Rashes, Muscle cramps.
Indications
Rotavirus vaccine is primarily indicated in conditions like Gastro-intestinal infections.
Interactions
Rotavirus vaccine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementBleomycinThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Bleomycin.MajorIn general, live virus or bacterial vaccines should not be used in patients receiving Bleomycin.BusulphanThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Busulphan.MajorIn general, live virus or bacterial vaccines should not be used in patients receiving Busulphan.CarmustineThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Carmustine.MajorIn general, live virus or bacterial vaccines should not be used in patients receiving Carmustine.CorticotropinThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Corticotropin.ModerateIn general, live virus or bacterial vaccines should not be used in patients receiving Corticotropin.Doxorubicin (HCl)The administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Doxorubicin (HCl).MajorIn general, live virus or bacterial vaccines should not be used in patients receiving Doxorubicin (HCl).FluorouracilThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Fluorouracil.MajorIn general, live virus or bacterial vaccines should not be used in patients receiving Fluorouracil.HydrocortisoneThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Hydrocortisone.ModerateIn general, live virus or bacterial vaccines should not be used in patients receiving Hydrocortisone.MethylprednisoloneThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Methylprednisolone.ModerateIn general, live virus or bacterial vaccines should not be used in patients receiving Methylprednisolone.PaclitaxelThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Paclitaxel.MajorIn general, live virus or bacterial vaccines should not be used in patients receiving Paclitaxel.PentostatinConcurrent use may potentiate a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.MajorIn general, live virus or bacterial vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases.TriamcinoloneThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received Triamcinolone.ModerateIn general, live virus or bacterial vaccines should not be used in patients receiving Triamcinolone. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Liquids Store Below 15°C. Protect from Sunlight, Moisture and Heat.
Warnings
The administration of rotavirus vaccine should be postponed in children with diarrhoea or vomiting. The vaccine should be used with caution in those with immunosuppressed close contacts. Carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby€™s nappies.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.